News 10.10.2024 Schlieren (Zurich), Switzerland, October 10, 2024 – Kuros Biosciences (“Kuros”), a leader in advanced bone healing technologies, today announced its financial performance for the first nine months of 2024. Revenue from direct MagnetOs product sales rose 149% in the first nine months of 2024, to CHF 50.6 million from CHF...
News 04.10.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will introduce proof-of-concept data for its new CD3 Switch-DARPin designed to...
Events, Internal events 04.10.2024 Personal Branding is too often overlooked as many think of it as “selling” themselves. It’s rather a self discovery journey that allows you to better understand your strengths and how you can leverage them to have win-win career conversations that will see you thrive, perform better and achieve your goals...
Events, Internal events
Event date: 26.05.2025
Join the Life Science Zurich Impact Conference at Technopark Zurich on May 26, 2025, and connect with leading experts from academia, industry, and investment.
Top speakers and exciting sessions await you: LSZ Impact Program 2025
Register now and be part of the future: https://lsz-impact2025.b2match.io/
News 27.09.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present on its lead-212 (212Pb)-labeled Radio-DARPin Therapeutic (RDT) targeting delta-like...